Cargando…

Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors

OBJECTIVE: To examine the clinical efficacy of budesonide/glycopyrronium bromide/formoterol (Breztri Aerosphere) as an adjunct to acute respiratory distress syndrome (ARDS). METHODS: A prospective study enrolled 120 patients with pulmonary endogenous ARDS admitted to the Department of Critical Care...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Haiying, Wang, Zhengyan, Ren, Lijun, Zhang, Guiqin, Zhao, Dan, Guo, Yanli, Wang, Lijuan, Feng, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071865/
https://www.ncbi.nlm.nih.gov/pubmed/35529915
http://dx.doi.org/10.1155/2022/8150444
_version_ 1784700923664138240
author Liu, Haiying
Wang, Zhengyan
Ren, Lijun
Zhang, Guiqin
Zhao, Dan
Guo, Yanli
Wang, Lijuan
Feng, Hong
author_facet Liu, Haiying
Wang, Zhengyan
Ren, Lijun
Zhang, Guiqin
Zhao, Dan
Guo, Yanli
Wang, Lijuan
Feng, Hong
author_sort Liu, Haiying
collection PubMed
description OBJECTIVE: To examine the clinical efficacy of budesonide/glycopyrronium bromide/formoterol (Breztri Aerosphere) as an adjunct to acute respiratory distress syndrome (ARDS). METHODS: A prospective study enrolled 120 patients with pulmonary endogenous ARDS admitted to the Department of Critical Care Medicine at the Fourth Hospital of Baotou from January 2017 to January 2020, and all enrollments were assigned (1 : 1) to receive conventional treatment (control group) or Breztri Aerosphere (study group). RESULTS: Breztri Aerosphere was associated with a significantly higher total efficacy versus conventional treatment. Breztri Aerosphere resulted in significantly lower acute physiology and chronic health evaluation scoring system (APACHE II) scores and Murray lung injury scores versus conventional treatment. Both groups saw an increase in the partial pressure of carbon dioxide (PCO2), partial pressure of oxygen (PO2), and oxygen saturation (SaO2) after treatment, with higher levels seen in patients given Breztri Aerosphere. After treatment, systemic vascular resistance (SVR) in both groups rose markedly, with greater elevation witnessed in the study group. The patients given Breztri Aerosphere showed significantly lower levels of pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (MAPA), pulmonary artery wedge pressure (PAWP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), and procalcitonin (PCT) versus those receiving conventional treatment. The patients experienced shorter mechanical ventilation time and intensive care unit (ICU) time after treatment of Breztri Aerosphere versus conventional treatment. CONCLUSION: Adjuvant therapy with Breztri Aerosphere in ARDS can significantly lower APACHE II scores and Murray lung injury scores, improve blood gas indexes and pulmonary circulation function indexes, and shorten mechanical ventilation time and ICU time, which may be attributed to its improvement of organism inflammation status and reduction of inflammatory factors.
format Online
Article
Text
id pubmed-9071865
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-90718652022-05-06 Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors Liu, Haiying Wang, Zhengyan Ren, Lijun Zhang, Guiqin Zhao, Dan Guo, Yanli Wang, Lijuan Feng, Hong Evid Based Complement Alternat Med Research Article OBJECTIVE: To examine the clinical efficacy of budesonide/glycopyrronium bromide/formoterol (Breztri Aerosphere) as an adjunct to acute respiratory distress syndrome (ARDS). METHODS: A prospective study enrolled 120 patients with pulmonary endogenous ARDS admitted to the Department of Critical Care Medicine at the Fourth Hospital of Baotou from January 2017 to January 2020, and all enrollments were assigned (1 : 1) to receive conventional treatment (control group) or Breztri Aerosphere (study group). RESULTS: Breztri Aerosphere was associated with a significantly higher total efficacy versus conventional treatment. Breztri Aerosphere resulted in significantly lower acute physiology and chronic health evaluation scoring system (APACHE II) scores and Murray lung injury scores versus conventional treatment. Both groups saw an increase in the partial pressure of carbon dioxide (PCO2), partial pressure of oxygen (PO2), and oxygen saturation (SaO2) after treatment, with higher levels seen in patients given Breztri Aerosphere. After treatment, systemic vascular resistance (SVR) in both groups rose markedly, with greater elevation witnessed in the study group. The patients given Breztri Aerosphere showed significantly lower levels of pulmonary vascular resistance (PVR), mean pulmonary arterial pressure (MAPA), pulmonary artery wedge pressure (PAWP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), and procalcitonin (PCT) versus those receiving conventional treatment. The patients experienced shorter mechanical ventilation time and intensive care unit (ICU) time after treatment of Breztri Aerosphere versus conventional treatment. CONCLUSION: Adjuvant therapy with Breztri Aerosphere in ARDS can significantly lower APACHE II scores and Murray lung injury scores, improve blood gas indexes and pulmonary circulation function indexes, and shorten mechanical ventilation time and ICU time, which may be attributed to its improvement of organism inflammation status and reduction of inflammatory factors. Hindawi 2022-04-28 /pmc/articles/PMC9071865/ /pubmed/35529915 http://dx.doi.org/10.1155/2022/8150444 Text en Copyright © 2022 Haiying Liu et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liu, Haiying
Wang, Zhengyan
Ren, Lijun
Zhang, Guiqin
Zhao, Dan
Guo, Yanli
Wang, Lijuan
Feng, Hong
Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors
title Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors
title_full Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors
title_fullStr Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors
title_full_unstemmed Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors
title_short Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors
title_sort clinical efficacy of budesonide/glycopyrronium bromide/formoterol in the treatment of patients with acute respiratory distress syndrome and its effect on inflammatory factors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071865/
https://www.ncbi.nlm.nih.gov/pubmed/35529915
http://dx.doi.org/10.1155/2022/8150444
work_keys_str_mv AT liuhaiying clinicalefficacyofbudesonideglycopyrroniumbromideformoterolinthetreatmentofpatientswithacuterespiratorydistresssyndromeanditseffectoninflammatoryfactors
AT wangzhengyan clinicalefficacyofbudesonideglycopyrroniumbromideformoterolinthetreatmentofpatientswithacuterespiratorydistresssyndromeanditseffectoninflammatoryfactors
AT renlijun clinicalefficacyofbudesonideglycopyrroniumbromideformoterolinthetreatmentofpatientswithacuterespiratorydistresssyndromeanditseffectoninflammatoryfactors
AT zhangguiqin clinicalefficacyofbudesonideglycopyrroniumbromideformoterolinthetreatmentofpatientswithacuterespiratorydistresssyndromeanditseffectoninflammatoryfactors
AT zhaodan clinicalefficacyofbudesonideglycopyrroniumbromideformoterolinthetreatmentofpatientswithacuterespiratorydistresssyndromeanditseffectoninflammatoryfactors
AT guoyanli clinicalefficacyofbudesonideglycopyrroniumbromideformoterolinthetreatmentofpatientswithacuterespiratorydistresssyndromeanditseffectoninflammatoryfactors
AT wanglijuan clinicalefficacyofbudesonideglycopyrroniumbromideformoterolinthetreatmentofpatientswithacuterespiratorydistresssyndromeanditseffectoninflammatoryfactors
AT fenghong clinicalefficacyofbudesonideglycopyrroniumbromideformoterolinthetreatmentofpatientswithacuterespiratorydistresssyndromeanditseffectoninflammatoryfactors